Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
MoonLake Immunotherapeutics (MLTX) had Income from Continuous Operations of $-121.24M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-118.94M |
|
-- |
|
-- |
|
$143.09M |
|
$-143.09M |
|
$22.13M |
|
$-120.96M |
|
$-120.96M |
|
$-121.24M |
|
|
Income from Continuous Operations |
$-121.24M |
$-121.24M |
|
$-121.24M |
|
$-143.09M |
|
$-141.71M |
|
62.87M |
|
62.87M |
|
$-1.89 |
|
$-1.89 |
|
| Balance Sheet Financials | |
$474.29M |
|
$0.72M |
|
$3.64M |
|
$477.93M |
|
$22.46M |
|
-- |
|
$2.08M |
|
$24.54M |
|
$453.39M |
|
$453.39M |
|
$453.39M |
|
63.92M |
|
| Cash Flow Statement Financials | |
$-116.59M |
|
$-205.60M |
|
$51.31M |
|
$451.17M |
|
$180.43M |
|
$-270.74M |
|
$7.28M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
21.11 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-117.11M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-26.74% |
|
-26.74% |
|
-25.37% |
|
-26.74% |
|
$7.09 |
|
$-1.86 |
|
$-1.85 |
|